Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celgene's EBIT per Share for the
three
months ended in Sep. 2019 was ARS161.53.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2019 was ARS463.15.
During the past 12 months, the average EBIT per Share Growth Rate of Celgene was 143.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 30.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 21.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 28.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Celgene's EBIT per Share or its related term are showing as below:
BUE:CELG'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -23.5 Med: 20 Max: 100.5
Current: 30
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Celgene was 100.50% per year. The lowest was -23.50% per year. And the median was 20.00% per year.
BUE:CELG's 3-Year EBIT Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.5
vs BUE:CELG: 30.00
Celgene's EBIT for the
three
months ended in Sep. 2019 was ARS117,836.08 Mil.
Celgene (BUE:CELG) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Celgene EBIT per Share Related Terms
Celgene EBIT per Share Historical Data
* Premium members only.
The historical data trend for Celgene's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS463.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celgene (BUE:CELG) has a EBIT per Share of ARS463.15 as of Sep. 2019. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Celgene and its competitors.
Is Celgene's EBIT per Share too high?
Celgene's current EBIT per Share is ARS463.15. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's EBIT per Share compare to GILD and BIIB?
Celgene's EBIT per Share of ARS463.15 can be compared against companies in the Drug Manufacturers industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Celgene and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celgene's current EBIT per Share is ARS463.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current EBIT per Share of ARS463.15. The current EBIT per Share is ARS463.15. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Celgene (BUE:CELG), the current EBIT per Share is ARS463.15 as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:CELG has been successfully added to your 
